Nivolumab Plus Ipilimumab With or Without Live Bacterial Supplementation in mRCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
Nat. Med. 2022 Feb 28;[EPub Ahead of Print], N Dizman, L Meza, P Bergerot, M Alcantara, T Dorff, Y Lyou, P Frankel, Y Cui, V Mira, M Llamas, J Hsu, Z Zengin, N Salgia, S Salgia, J Malhotra, N Chawla, A Chehrazi-Raffle, R Muddasani, J Gillece, L Reining, J Trent, M Takahashi, K Oka, S Higashi, M Kortylewski, SK Highlander, SK PalFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.